OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
Treasury Stock
OSE Immunotherapeutics SA
Treasury Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Treasury Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Treasury Stock
-€448k
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Treasury Stock
-€645k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Treasury Stock
-€799k
|
CAGR 3-Years
7%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Treasury Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Treasury Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Treasury Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Treasury Stock?
Treasury Stock
-448k
EUR
Based on the financial report for Dec 31, 2024, OSE Immunotherapeutics SA's Treasury Stock amounts to -448k EUR.
What is OSE Immunotherapeutics SA's Treasury Stock growth rate?
Treasury Stock CAGR 5Y
-25%
Over the last year, the Treasury Stock growth was -10%. The average annual Treasury Stock growth rates for OSE Immunotherapeutics SA have been -41% over the past three years , -25% over the past five years .
You don't have any saved screeners yet